SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
4.880
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
4.885
+0.005 (0.10%)
After-hours: Apr 28, 2026, 7:54 PM EDT
SLS Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
876.36M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Theravance Biopharma | 107.46M |
| ARS Pharmaceuticals | 84.28M |
| Kura Oncology | 67.48M |
| Arbutus Biopharma | 14.08M |
| Crescent Biopharma | 10.84M |
| Allogene Therapeutics | 22.00K |
SLS News
- 4 weeks ago - These 16 stocks are a short seller's dream — likely losers no matter what the market does - Market Watch
- 5 weeks ago - SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - GlobeNewsWire
- 7 weeks ago - What's Going With SELLAS Life Sciences Stock On Wednesday? - Benzinga
- 3 months ago - SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe - GlobeNewsWire
- 4 months ago - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 5 months ago - SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - GlobeNewsWire